OPKO Health has completed the acquisition of Prost-Data, Inc., doing business as OURLab, a Nashville-based CLIA laboratory with 18 phlebotomy sites throughout the U.S. and an experienced national sales force calling primarily on urologists.

In addition to operating as a stand-alone laboratory testing service, OURLab will provide OPKO a commercial platform to support the near-term U.S. commercial launch of its novel panel of kallikrein biomarkers and associated algorithm (4Kscore™) for the detection of prostate cancer.

Phillip Frost, M.D., OPKO’s Chairman and Chief Executive Officer, commented, “We look forward to working together with OURLab’s talented personnel to support the U.S. launch of the important 4Kscore™ prostate test.”

Leave a Reply

Your email address will not be published. Required fields are marked *